S&P 500   3,743.27 (-1.26%)
DOW   30,015.48 (-0.99%)
QQQ   277.70 (-1.57%)
AAPL   144.17 (-1.32%)
MSFT   245.44 (-1.38%)
META   135.74 (-3.24%)
GOOGL   99.36 (-2.24%)
AMZN   118.76 (-1.92%)
TSLA   234.72 (-5.90%)
NVDA   128.28 (-2.57%)
NIO   15.78 (-5.68%)
BABA   83.63 (-0.57%)
AMD   66.19 (-2.52%)
T   15.87 (-1.37%)
MU   53.72 (-0.44%)
CGC   2.99 (-4.78%)
F   12.32 (-0.32%)
GE   66.95 (-0.87%)
DIS   99.24 (-2.17%)
AMC   7.16 (-8.56%)
PYPL   91.31 (-1.59%)
PFE   43.81 (-1.46%)
NFLX   228.67 (-5.01%)
S&P 500   3,743.27 (-1.26%)
DOW   30,015.48 (-0.99%)
QQQ   277.70 (-1.57%)
AAPL   144.17 (-1.32%)
MSFT   245.44 (-1.38%)
META   135.74 (-3.24%)
GOOGL   99.36 (-2.24%)
AMZN   118.76 (-1.92%)
TSLA   234.72 (-5.90%)
NVDA   128.28 (-2.57%)
NIO   15.78 (-5.68%)
BABA   83.63 (-0.57%)
AMD   66.19 (-2.52%)
T   15.87 (-1.37%)
MU   53.72 (-0.44%)
CGC   2.99 (-4.78%)
F   12.32 (-0.32%)
GE   66.95 (-0.87%)
DIS   99.24 (-2.17%)
AMC   7.16 (-8.56%)
PYPL   91.31 (-1.59%)
PFE   43.81 (-1.46%)
NFLX   228.67 (-5.01%)
S&P 500   3,743.27 (-1.26%)
DOW   30,015.48 (-0.99%)
QQQ   277.70 (-1.57%)
AAPL   144.17 (-1.32%)
MSFT   245.44 (-1.38%)
META   135.74 (-3.24%)
GOOGL   99.36 (-2.24%)
AMZN   118.76 (-1.92%)
TSLA   234.72 (-5.90%)
NVDA   128.28 (-2.57%)
NIO   15.78 (-5.68%)
BABA   83.63 (-0.57%)
AMD   66.19 (-2.52%)
T   15.87 (-1.37%)
MU   53.72 (-0.44%)
CGC   2.99 (-4.78%)
F   12.32 (-0.32%)
GE   66.95 (-0.87%)
DIS   99.24 (-2.17%)
AMC   7.16 (-8.56%)
PYPL   91.31 (-1.59%)
PFE   43.81 (-1.46%)
NFLX   228.67 (-5.01%)
S&P 500   3,743.27 (-1.26%)
DOW   30,015.48 (-0.99%)
QQQ   277.70 (-1.57%)
AAPL   144.17 (-1.32%)
MSFT   245.44 (-1.38%)
META   135.74 (-3.24%)
GOOGL   99.36 (-2.24%)
AMZN   118.76 (-1.92%)
TSLA   234.72 (-5.90%)
NVDA   128.28 (-2.57%)
NIO   15.78 (-5.68%)
BABA   83.63 (-0.57%)
AMD   66.19 (-2.52%)
T   15.87 (-1.37%)
MU   53.72 (-0.44%)
CGC   2.99 (-4.78%)
F   12.32 (-0.32%)
GE   66.95 (-0.87%)
DIS   99.24 (-2.17%)
AMC   7.16 (-8.56%)
PYPL   91.31 (-1.59%)
PFE   43.81 (-1.46%)
NFLX   228.67 (-5.01%)
NYSE:TFX

Teleflex - TFX Stock Forecast, Price & News

$204.03
-2.22 (-1.08%)
(As of 10/5/2022 11:43 AM ET)
Add
Compare
Today's Range
$202.09
$205.29
50-Day Range
$201.46
$266.53
52-Week Range
$199.92
$382.46
Volume
3,717 shs
Average Volume
396,496 shs
Market Capitalization
$9.57 billion
P/E Ratio
18.96
Dividend Yield
0.65%
Price Target
$322.70

Teleflex MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
57.7% Upside
$322.70 Price Target
Short Interest
Healthy
2.88% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.53
Upright™ Environmental Score
News Sentiment
0.19mentions of Teleflex in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.85%
From $13.12 to $14.15 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

99th out of 1,087 stocks

Surgical & Medical Instruments Industry

9th out of 106 stocks

TFX stock logo

About Teleflex (NYSE:TFX) Stock

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Receive TFX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teleflex and its competitors with MarketBeat's FREE daily newsletter.

TFX Stock News Headlines

Teleflex Completes Acquisition of Standard Bariatrics
Teleflex is Now Oversold (TFX) - Nasdaq
See More Headlines
Receive TFX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teleflex and its competitors with MarketBeat's FREE daily newsletter.

TFX Company Calendar

Last Earnings
7/28/2022
Ex-Dividend for 9/15 Dividend
8/12/2022
Dividend Payable
9/15/2022
Today
10/05/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
87936910
Employees
14,000
Year Founded
1943

Price Target and Rating

Average Stock Price Forecast
$322.70
High Stock Price Forecast
$430.00
Low Stock Price Forecast
$241.00
Forecasted Upside/Downside
+58.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
10 Analysts

Profitability

Net Income
$485.37 million
Pretax Margin
21.00%

Debt

Sales & Book Value

Annual Sales
$2.81 billion
Cash Flow
$18.25 per share
Book Value
$80.15 per share

Miscellaneous

Free Float
46,305,000
Market Cap
$9.57 billion
Optionable
Optionable
Beta
1.09

Social Links


Key Executives

  • Mr. Liam J. KellyMr. Liam J. Kelly (Age 55)
    Chairman, Pres & CEO
    Comp: $3.01M
  • Mr. Thomas E. Powell (Age 60)
    Exec. VP & CFO
    Comp: $1.44M
  • Mr. Cameron P. HicksMr. Cameron P. Hicks (Age 57)
    Corp. VP & Chief HR Officer
    Comp: $771.45k
  • Mr. Jay White (Age 48)
    Corp. VP & Pres of Global Commercial
    Comp: $1.23M
  • Mr. James P. Winters
    Corp. VP, Manufacturing and Supply Chain
  • Mr. John R. Deren
    Corp. VP & Chief Accounting Officer
  • Mr. John Hsu C.F.A.
    VP of Investor Relations
  • Mr. Daniel V. Logue (Age 48)
    Corp. VP, Gen. Counsel & Sec.
  • Mr. Howard Cyr
    Corp. VP & Chief Compliance Officer
  • Mr. Matt Tomkin
    VP of Corp. Devel.













TFX Stock - Frequently Asked Questions

Should I buy or sell Teleflex stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teleflex in the last twelve months. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TFX shares.
View TFX analyst ratings
or view top-rated stocks.

What is Teleflex's stock price forecast for 2022?

10 Wall Street research analysts have issued 12 month target prices for Teleflex's shares. Their TFX share price forecasts range from $241.00 to $430.00. On average, they predict the company's share price to reach $322.70 in the next year. This suggests a possible upside of 57.7% from the stock's current price.
View analysts price targets for TFX
or view top-rated stocks among Wall Street analysts.

How have TFX shares performed in 2022?

Teleflex's stock was trading at $328.48 on January 1st, 2022. Since then, TFX stock has decreased by 37.7% and is now trading at $204.58.
View the best growth stocks for 2022 here
.

When is Teleflex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our TFX earnings forecast
.

How were Teleflex's earnings last quarter?

Teleflex Incorporated (NYSE:TFX) announced its quarterly earnings results on Thursday, July, 28th. The medical technology company reported $3.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.34 by $0.05. The medical technology company had revenue of $704.50 million for the quarter, compared to analysts' expectations of $719.50 million. Teleflex had a net margin of 18.16% and a trailing twelve-month return on equity of 16.84%. The company's revenue was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.35 EPS.
Read the conference call transcript
.

How often does Teleflex pay dividends? What is the dividend yield for Teleflex?

Teleflex announced a quarterly dividend on Thursday, July 28th. Stockholders of record on Monday, August 15th will be paid a dividend of $0.34 per share on Thursday, September 15th. This represents a $1.36 annualized dividend and a dividend yield of 0.66%. The ex-dividend date is Friday, August 12th.
Read our dividend analysis for TFX
.

Is Teleflex a good dividend stock?

Teleflex (NYSE:TFX) pays an annual dividend of $1.36 per share and currently has a dividend yield of 0.65%. The dividend payout ratio is 12.64%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TFX will have a dividend payout ratio of 9.61% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TFX.

What guidance has Teleflex issued on next quarter's earnings?

Teleflex issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $13.00-$13.40 for the period, compared to the consensus estimate of $13.97. The company issued revenue guidance of $2.80 billion-$2.83 billion, compared to the consensus revenue estimate of $2.89 billion.

What is Liam Kelly's approval rating as Teleflex's CEO?

73 employees have rated Teleflex Chief Executive Officer Liam Kelly on Glassdoor.com. Liam Kelly has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Teleflex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teleflex investors own include NVIDIA (NVDA), AbbVie (ABBV), Johnson & Johnson (JNJ), Alibaba Group (BABA), Lam Research (LRCX), ServiceNow (NOW), QUALCOMM (QCOM), Advanced Micro Devices (AMD), Salesforce (CRM) and Cisco Systems (CSCO).

What is Teleflex's stock symbol?

Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."

How do I buy shares of Teleflex?

Shares of TFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teleflex's stock price today?

One share of TFX stock can currently be purchased for approximately $204.58.

How much money does Teleflex make?

Teleflex (NYSE:TFX) has a market capitalization of $9.59 billion and generates $2.81 billion in revenue each year. The medical technology company earns $485.37 million in net income (profit) each year or $10.76 on an earnings per share basis.

How many employees does Teleflex have?

The company employs 14,000 workers across the globe.

How can I contact Teleflex?

Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The official website for the company is www.teleflex.com. The medical technology company can be reached via phone at (610) 225-6800, via email at shareholder@broadridge.com, or via fax at 215-553-5402.

This page (NYSE:TFX) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.